Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the disc...
vTv Therapeutics is a clinical-stage biopharmac...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering n...
Revance Therapeutics is a Silicon Valley-based ...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...
Headquartered in New York, BeyondSpring Inc. (B...
Join the National Investor Network and get the latest information with your interests in mind.